2nd International Conference and Exhibition on
Pharmaceutical Regulatory Affairs
November 23-24, 2012 Hyderabad International Convention Centre, India
Participants List in Academia
Untitled Document
University of Texas at Arlington, USA
Stanford University School of Medicine, USA
Mahidol University, Thailand
Amirkabir University of Technology, Iran
Hamdard University, India
Yeshiva University, USA
University of Macau, China
Monash University, Australia
University of Michigan, Ann Arbor
Universidade Federal do Rio de Janeiro, Brazil
University of Denver, Colorado
University of Toronto, Canada
Zagazig University, Egypt
Banaras Hindu University, India
Taipei Medical University, Taiwan
University di Messina CNISM, Italy
University of Tasmania, Australia
Huazhong University of Science and Technology, China
Sogang University, Korea
University of Edinburgh, UK
Martin-Luther-University Halle-Wittenberg, USA
Universidade de Sao Paulo, Brazil
Eve University, Turkey
University of Delhi, India
Isfahan University of Technology(IUT), Iran
Taif University, Saudi Arabia
University Medical Center, Netherlands
University of Copenhagen, Denmark
University Paris 13, France
Participants List From Business
Untitled Document
Cadila Pharmaceuticals, India
Chemical Works of Gedeon Richter, Hungary
3S-Pharmacological Consultation & Research GmbH, Germany
Royal Brisbane and Women's Hospital, Australia
Psoriasis and Cutaneous Inflammation Research Laboratory, USA
Alcon Laboratories Inc., USA
National Institute for Materials Science (NIMS), Japan
Grup de Recerca de Reumatologia (IRHVH), Spain
Bayer Health Care, Richmond, USA
Crown Bioscience Inc., China
Hammersmith Hospital, London
Van Drie Research LLC, USA
Dr.Reddy's labs, India
Merck Research Laboratories, USA
National Institute of Pharmaceutical Education and Research (NIPER), India
AstraZeneca R&D Boston, USA
Abbott Laboratories, USA
Hutchison MediPharma Limited, China
Sage Bionetworks, USA
Central Drug Research Institute, India
Glenmark Pharmaceuticals, India
National Institute for Interdisciplinary Science & Technology (NIIST) , India
Novartis Campus, Austria
Upcoming Conferences
2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs, Pharma-2012 , will be organized around the theme "Concepts, Challenges and Opportunities in Regulatory Strategy."
Pharma-2012 is comprised of 11 tracks and 48 sessions designed to offer comprehensive sessions that address current issues in pharmaceutical Regulatory Affairs.
Submit your abstract to any of the following tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Renowned Speakers
Pradeep K. Karla
Howard University, USA
Deepa Arora
Lupin Limited, India
Sunita Sharma
Ocimum Bio Solutions, USA
Laerte Dall’Agnol
DALL Solucoes AnalÃticas e Empresariais, Brazil
S. V. Eswaran
University of Delhi, India
Naser L. Rezk
King Saud bin Abdul-Aziz University for Health Sciences, Saudi Arabia
Bahrudin Ibrahim
Universiti Sains Malaysia, Malaysia
Bobby George
Reliance Life Sciences, India
N. Rajasekar
SiliCycle Inc., Canada
Mallika Rajasekaran
Aris Global Software Private Limited, India
Andrea Laslop
Austrian Agency for Health and Food Safety, Austria
S V Krishna prasad
Cito Healthcare Pvt. Ltd, India
Maryse Picher
Zintro Inc and CFRx Raleigh-Durham, USA
Sudhakar Akul Yakkanti
Boys Town National Research Hospital, USA
Shivanand Puthli
Panacea Biotec Ltd., India
Lise Aagaard
University of Southern Denmark, Denmark
Patrick L. Leoni
Euromed Management, France
Silvia Lima Costa
Universiade Federal da Bahia, Brazil
Track 1: Regulatory Affairs for Healthcare Products
Track 1-1
Pharmaceuticals
Track 1-2
Medical devices
Track 1-3
Biologics and biotechnology products
Track 1-4
Cosmetics
Track 1-5
Veterinary products
Track 2: Biologics and Medical Devices
Track 2-1
Clinical trial design for medical devices
Track 2-2
Biologics and design control
Track 2-3
Process validation for drugs and biologics
Track 2-4
Bioengineered pharmaceutical products
Track 3: Drug Development and NDDS
Track 3-1
New strategies for drug development
Track 3-2
Drug delivery systems by nano technology
Track 3-3
Transmucosal and topical drug delivery systems
Track 3-4
Novel therapeutic approaches and future trends
Track 4: Drug Interactions and Toxicity
Track 4-1
Epidemiology of drug interactions
Track 4-2
Food/alcohol drug interactions
Track 4-3
Drug toxicity and adverse drug reactions
Track 4-4
Pharmacokinetics and pharmacodynamics
Track 5: Biologics, Novel Therapies and other Special Categories
Track 5-1
Biological products
Track 5-2
Blood and blood products
Track 5-3
Cells, tissues, organs, gene therapy, cloning
Track 5-4
Radiopharmaceuticals
Track 6: OTC Drug Products, Herbal Medicines, and Homeopathic Medicines
Track 6-1
Homeopathic medicines
Track 6-2
Herbal and ayurvedic products
Track 6-3
Vaccines
Track 6-4
Narcotics/controlled drugs
Track 7: Safety and Quality Regulation
Track 7-1
New drug development
Track 7-2
Medical device development
Track 7-3
Biologics development
Track 7-4
Prescription drugs
Track 7-5
Drug dosage and labelling
Track 8: Business and Law Enforcement and Education
Track 8-1
The business of pharmacy, medicine and biotechnology
Track 8-2
Understanding the health care landscape
Track 8-3
Regulatory culture in food and drug administration
Track 8-4
Biomedical product development: From boardroom to market
Track 8-5
Importance of personnel training and education in regulatory affairs
Track 9: Biomedical Intellectual Property Management
Track 9-1
Global biotechnology product registration: E.U., U.S. product regulation
Track 9-2
Quality (chemistry/manufacturing Controls), safety and efficacy issues
Track 9-3
Intellectual property law for generics and innovator rights
Track 9-4
Patents in the pharmaceutical industry: Legal & ethical Issues
Track 10: Regulatory Compliances in Health Care
Track 10-1
FDA and EU regulatory policies
Track 10-2
Regulatory aspects of NDA and ANDA: Regulatory filing and submissions
Track 10-3
Compliance programs and policy guides
Track 10-4
GMP, GCP, GLP and GRPs
Track 11: Novel Strategies for Growth in the Pharma and Regulatory Environment
Track 11-1
Regulatory issues, quality control, and business development
Track 11-2
Clinical trials in emerging markets
Track 11-3
Benefit/risk assessment during drug development
Track 11-4
Strategic development towards FDA approval
Track 11-5
Regulatory challenges in nano and biotech therapeutics